SlideShare uma empresa Scribd logo
1 de 54
ENDOMETRIAL PREPARATION
IN FROZEN EMBRYO
TRANSFER CYCLES
Aboubakr Elnashar
Benha university, Egypt
AboubakrElnashar
CONTENTS
INTRODUCTION
I. NATURAL CYCLE
II. ARTIFICIAL (HORMONE
REPLACEMENT) CYCLE
III. OVULATION INDUCTION
CONCLUSION
AboubakrElnashar
INTRODUCTION
1st successful pregnancy following FET:
1983 Trounson and Mohr
(Trounson, 1983).
 Cryopreservation of embryos has become an
integral part of ART programs.
 Increased dramatically
 1.Ttrend towards transferring fewer embryos
after a fresh IVF cycle
 2. Improved laboratory techniques
 (Skovmand 1997; Diniz, 2002; Fineschi et al., 2005; Gordts et
al., 2005; Thompson, 2005; Le Lannou et al., 2006; JOINT
SOGC-CFAS, 2008; Min et al., 2010).
AboubakrElnashar
Success= keypoints in performing FET
1. Selecting proper embryos used for FET
•Cleavaged embryos with grade I or II, and present
≥6 blastomeres at D3 are the right kind.
•Embryos with 4 blastomere: continue in vitro
culture to reach the stage of 8 blastomere then
perform vitrification cryopreservation.
•Non-high quality embryos: continue to culture
them into blasocyst and select the valid blastocyst
for cryopreservation.
This step is important for settling the appropriate
time for ET
AboubakrElnashar
2. Accurate synchronization of endometrium and
embyos is the key of performing FET.
Important for implantation
 Age of the embryos after thawing corresponds to
age of the endometrium on the day of ET
3. Sufficient luteal support
AboubakrElnashar
Methods:
Regular ovulatory Irregular or unovulatory
I. Natural II. Artificial=Hormone
replacement
III. Ovulation induction
True Modified E and P Gna, E and P GnT Letrozole Nolvadex
Functioning ovaries:
Any method
Quiescent Ovaries (e.g. donor oocyte recepient
with ovarian failure)
Only HRT with E and P
Many infertility units use a mixture of protocols for
FET.
AboubakrElnashar
Best method:
Little agreement in ovulatory women
(Ghobara and Vandekerckhove, 2008;Weissman et al., 2009).
AboubakrElnashar
I. NATURAL CYCLE NC-FET
 Indication
It is only feasible for women with regular cycles and
proven ovulation.
In normally ovulating women: protocol of choice
 The simplest method
 Endocrine preparation of the endometrium is
achieved by endogenous sex steroid production
from a developing follicle.
AboubakrElnashar
A. True Natural cycle
 Timing of ET is determined by detecting the
spontaneous LH surge
Method:
1. D10-12 (3-5 d prior to estimated ovulation day)
 Serial US: E thickness, follicular development
and to time the commencement of testing for LH
 LH (urine or blood) for detection of the LH surge ,
 P levels
When a rise in serum LH levels is observed, it is assumed that ovulation will occur
36–40 h later (Andersen et al., 1995).
LH surges in urine lag up to 21 h behind the appearance of the surge in blood
(Hoff et al., 1983; Frydman et al., 1984; Miller and Soules 1996).
The day when LH exceeds 180% of baseline (calculated as the mean of the 3
previous morning samples) corresponds to a day prior to OPU/ovulation.
2. US for evidence of ovulation.
AboubakrElnashar
3. FET
3–5 days after ovulation depending on the stage
of the embryo when frozen
The day of ovulation corresponds to the day of
egg retrieval.
If embryos were frozen at 72h, ovulation day+3 is
the right time to transfer.
(Nawroth and Ludwig, 2005; Paulson,2011).
4. LPS:
progesterone
AboubakrElnashar
Advantage
no medications are used: preferable to many
women.
AboubakrElnashar
Disadvantages:
1. Even in women having regular menstrual cycles,
ovulation may not always occur
2. Problem associated with the detection of
spontaneous LH surges
A. variation in timing of its occurrence between
cycles and between patients (Park et al., 2007).
B. In order to assess the LH levels correctly,
determination should be performed at least daily,
and preferably twice a day.
C. LH urine kits have a large variation in thresholds,
which involve the risk of up to 30% of false-
negative testing, and are often reported by
patients as being difficult to interpret
(Miller and Soules, 1996; Guermandi et al., 2001; O’Connor et al., 2006).
AboubakrElnashar
B. Modified natural cycle
To overcome the disadvantages of LH monitoring:
Administering hCG to initiate luteinization
Method:
1. Regular US:
2. HCG
5000 IU when dominant follicle (16 or 17or 18 mm):
ovulation 36–38 h later
(Andersen et al., 1995).
Combined with E2 levels of (450-550 pmol/L), 600-700 or 800-900 respectively
HCG administration correspond to the HCG
administration day of the source cycle
AboubakrElnashar
Zheng et al, 2014 AboubakrElnashar
Advantages:
less US evaluation due to the hCG administration
compared with true NC-FET: less burden on
patients and doctors
(Weissman et al., 2011).
AboubakrElnashar
Risks
1. unexpected ovulation
: accurate planning of embryo thawing and transfer
is not possible: cycle cancellation (7–12%)
(Fatemi et al., 2010; Hill et al., 2010).
2. Difficulty in ensuring timely thawing and ET.
AboubakrElnashar
LPS in NC-FET.
Not required
(Kyrou et al, 2010)
similar result in patients receiving true NC-FET
(Lee et al., 2013).
{CL formation is not hampered by inadequate LH
secretion}
higher LBR in patients undergoing true NC-FET
with LPS.
(Bjuresten et al. 2011)
Too little evidence supporting a positive effect of
LPS in patients undergoing NC-FET
(Groenewoud et al, 2013, MA)
AboubakrElnashar
True NC-FET Vs modified NC-FET:
no difference in outcome
AboubakrElnashar
II. ARTIFICIAL (HORMONE
REPLACEMENT) CYCLE
In patients with irregular cycles HRT is best used.
Aims
To mimic the endocrine exposure of the
endometrium in the normal cycle.
AboubakrElnashar
Key points:
1.An endometrial thickness 6 and showing triple line is
favorable for ET
2.Endometrial development is unaffected by the length
of the follicular phase. No adverse effects of reduction
the duration of exposure to E to 6 days or an increase
up to 35 days. However receptivity is best preserved
when the follicular phase is kept between 12 and 19
days
3.The endometrium is affected by either incremental or
fixed E levels , even in supraphysiologic range
AboubakrElnashar
A. Estrogens and progesterones without
GnRHa.
used in women with remaining ovarian function
(Jaroudi 1991; Lelaidier 1992).
Method:
1. Oestrogen
Effect:
proliferation of the endometrium, while suppressing the
development of the dominant follicle
 Form and dose
 Oral E2 (progynova or Trisequence (Blue tab) or Cycloprogenova (White tab))
4-6 mg/d or 2 mg/d with an increasing doses
 Transdermal patches (estrofem/estrace)
 subcutaneous implants
 vaginal rings or tablets.
AboubakrElnashar
 When:
 D1 of cycle: prevents follicular recruitment by
suppressing FSH: spontaneous ovulation is
avoided.
 D3
before D4.
AboubakrElnashar
2. Progesterone
Aim:
initiate secretory changes
Form
oral tablets
IM 40-60 mg in oil
vaginal suppositories, gel or rings (Devroey 1998).
When
Once the lining endometrium: 7–9 mm on US
Not duration of E2 supplementation but the
endometrium thickness should be the leading factor
in determining the start of progesterone
(Nawroth and Ludwig, 2005; El-Toukhy et al., 2008).
AboubakrElnashar
Route:
No difference in PR between vaginal and IM
progesterone.
(Glujovsky et al., 2010, SR)
based on patient and doctor preference.
AboubakrElnashar
Timing of embryo thawing and ET:
Planned according to the moment of progesterone
supplementation.
The day P is started is considered ovulation/opu
day, and the time of thaw/transfer is determined
accordingly.
AboubakrElnashar
1. E2
From D2 or 3 of cycle:
3 or 4 tab (acc to wt of pt) (for 7 or 8 days)
2. US:
When endometrial thickness 9 mm
3. Prontogest 400 mg twice daily or
duphaston 10 mg tds
4. ET
If you are freezing
Blastocyst: transfer on 6th or 7th day of progesterone
D3 or Morula: transfer on day 4 of progesterone
(some say D 5 for all, no difference)
4. LPS
Estrogen and progesterone
AboubakrElnashar
Cases of amenorrhea (after induction by lutone
or lutofolon or cycloprognova or pills)
1. E2
1 Tab x 3 day from D3 of the cycle
2 Tab x 3 day
3 Tab x (2 – 5 day )
2. TVS monitoring
till endometrial lining is 9 – 10 mm.
3. Uterogestan1 tab of utrogestan/d
E2: 2 Tab/d till pregnancy test
4. ET
5. LPS:
if preg test positive: utrogestan 2X3
AboubakrElnashar
1. Oral E2
2 mg/d from cycle day 1-4
4 mg/d from day 5-8
6 mg/d from day 9-12.
2. TVS: assess endometrial-thickness and ovulation
from D13 and E2 dosage was adjusted based on
the endometrial-thickness.
3. P: 40 mg IM when the endometrium reached a
thickness of 8 mm or maximum.
60 mg, 80 mg, and 80 mg progesterone were used
respectively in the following 3 days.
4. ET after 4 days of progesterone administration.
AboubakrElnashar
1. Oral E2: 2 mg three times daily.
2. TVS: After 11, 12 or 13 days
A. If no leading follicle is present and the endometrial thickness is
≥ 8 mm: micronized progesterone (utrogestan) is added and
thawing and transferring is commenced 4 or 5 days later
according to the stage of cryopreservation
B. If the endometrial thickness is less than 8 mm: progynova
dose is raised to 2 mg 4 times daily for 7 days.
After a week the endometrium is checked once again.
 When the endometrium thickness is >8 mm and no dominant follicle (≥
14 mm) is present: utrogestan can be added and thawing and
transferring is performed according to local protocols.
 If a follicle is visible during ultrasound: LH and P levels are determined.
• If these are raised, (serum LH ≥ 13 E/l or progesterone ≥ 15
nmol/l) luteinization of the follicle is considered to have taken place
and because of the associated diminished pregnancy rates,
thawing and transferring will not be performed.
• If serum levels are below the above mentioned levels thawing and
transferring can be performed according to local protocol
AboubakrElnashar
Zheng et al, 2014
AboubakrElnashar
Advantages
1. Greater control and flexibility in the timing of
transfer. cycles are easier to plan: popular
among many patients and their doctors.
2. The length of the follicular phase can be varied
without detriment to IR or PR
(Leeton 1991; Navot 1989)
3. Cycle cancellation rate is low.
AboubakrElnashar
4. Higher IR and PR than patients with natural
cycles
IR and PR was higher in patients without ovulation
than ovulatory patients
ovulation in HRT cycle has a detrimental effect on
pregnancy.
HRT should be used in FET cycles, and ovulation of
patients should be evaluated during the treatment.
Zheng et al, 2014
AboubakrElnashar
Risks:
1. The administration of E and P does not guarantee
complete pituitary suppression: a dominant follicle
may occur. luteinization may occur in 5%
(El Toukhy et al., 2004).
2. Should the follicle undergo spontaneous
luteinization: endometrium may be exposed to
progesterone earlier: incorrect timing of thawing and
transferring.
From a cost-efficiency perspective, this aspect is of
great importance and should be taken into account
GnRHa co-treatment may be used to down-
regulate the pituitary and prevent follicular growth
(AC-FET with GnRH-FET). AboubakrElnashar
3. Both of these AC-FET approaches require
medication and are therefore less ‘physiological’
AboubakrElnashar
AboubakrElnashar
LPS:
If a pregnancy occurs, E and P must be continued
until placental autonomy is established to replace
the absent corpus luteum.
No difference in PR between different methods of
LPS in patients undergoing ‘fresh’ IVF or ICSI
(Chocrane SR, van der Linden et al., 2011).
The use of synthetic progesterone in patients
undergoing IVF or ICSI did lead to higher PR
compared with natural progesterone.
AboubakrElnashar
B. Estrogens and progesterones with
GnRHa.
Indication:
In women with remaining ovarian function
Aim:
GnRHa is used to suppress temporarily ovarian function and
render the patient functionally agonadal prior to inducing an
artificial cycle with E and P.
Method:
1. GnRHa (Decapeptyl CR, 3.75 mg)
in regularly menstruating it is given on D21 of the cycle
in oligomenorrhic from D1 of the cycle.
2. After 14 days:
E2 is determined
E2 is started as before
AboubakrElnashar
AboubakrElnashar
Disadvantages:
1. More expensive
2. GnRHa can have side effects
3. Delay the resumption of spontaneous ovulation
if FET fails.
AboubakrElnashar
AC-FET Vs AC-FET with GnRH
Cost is less
Cancellation due to luteinization occurs in 5% is
more
No significant difference in PR
AboubakrElnashar
NC-FET Vs AC-FET.
No difference in PR.
AboubakrElnashar
NC-FET Vs AC-FET with GnRHa:
No significant difference in PR or LBR.
(Ghobara and Vandekerckhove,2008)
Significantly higher cancellation rates in
NC-FET (17.4%) Vs AC-FET with GnRH (4.5%)
{preventive effect of down-regulation with regard to
luteinization and ovulation}.
(Hill et al., 2010).
AboubakrElnashar
III. OVULATION INDUCTION
Ovary is functional but anovulatory and irregular
cycles, ovulation may be induced by CC, Nolvadex,
letrozole or hMG or or a combination
(Van der Auwera;1994).
For synchronization the day of HCG administration
should correspond to the day HCG administration of
the source cycle in which the embryos were retrieved
AboubakrElnashar
A. Letrozole, GNT
In patients with irregular cycles Letrozole is 1st
choice for endometrium preparation for FET
1. Letrozole:
2.5-5mg on cycle D3 to 7, in order to promote monofollicular development
2. TVS:
if follicles growth is not ideal: mild stimulation (HMG 150 IU)
3. HCG:
10000: when the follicles reach the criteria of mature
4. ET
Embryos were frozen at 72h: ETAfter 4 or 5 days
Blastocyst transfer is performed after 7 days.
AboubakrElnashar
1. Letrozole
2.5mg,once daily from D3 to D7 of cycle
2. TVS
D10 of cycle: IM Gnt 37.5~75 IU/d until there is
LH surge or ovulation
3. HCG
 On the day appearing LH surge: IM HCG10000
IU.
 If there is sill no LH surge when the follicle is 20-
24mm: ovulation is induced by HCG.
4. ET
3 days after ovulation is observed.
4. LPS:
HCG 2000-2500 IU/3d.
AboubakrElnashar
B. Letrozole or nolvadex, E2
1. Letrozole:
1x1 x 5 or
Nolvadex
1x3x5 from D3 of the period
2. E2
1x2x3 from D 8 - 9th day of period (follicle 12-14mm)
1x3x3
3. TVS:
from D10-11 till endometrial lining 9-11 mm
4. HCG
4. ET
after 3.5 Days for the 2 days frozen embryo or after 4.5 Days for the 3 days
frozen embryo
5. LPS:
E2: 1x2x12 w of pregnancy.
Cyclogest 200mg 2 days before E.T
Then Cyclogest 400mg after E.T. till 12w
AboubakrElnashar
C. CC, E2
1.CC
Start D 3 to 5 of menstruation or withdrawal for 5
days
2. E2
2mg/d until D of HCG administration to overcome
detrimental effect of CC on endometrium.
3. HCG
Repeated testing of P with US
P within follicular levels
adequate follicular size (20-24 mm) and
E thickness ≥8mm: HCG 10000
AboubakrElnashar
D. Chronic low dose GnT
Anovulatory patients resistant to CC:
1.FSH
37.5 -75 U /d for up to 14 days
2. TVS
if no dominant F is recruited , the dose is increased
at increments 37.5 U every week to a maximum
225 U/d
When single dominant F of 10-12 mm the dose is
maintained
3. Monitor by US and E2 and P
AboubakrElnashar
CONCLUSION
It is not possible, to recommend one endometrial
preparation method in FET over another
Future RCTs should not only address PR but also
consider convenience and cost efficiency.
No significant advantage of one specific approach
to prepare the endometrium for FET in terms of PR
or LBR.
(Ghobara and Vandekerckhove, 2008; Groenewoud et al, 2013, MA)
AboubakrElnashar
Choice for either NC or AC should be made based
upon other factors:
1. number of canceled cycles
2. number of hospital visits to plan FET
3. possible serious adverse events and side-effects
4. hospital and IVF laboratory logistics
5. patient or doctor preference.
No publications that address these factors
AboubakrElnashar
Thank you
AboubakrElnashar
For the patients with thin endometrium or multiple
ET failures, HRT
1. Oral E2
(ethinyloestradiol) is given 75ug/day for 14-28 days.
Once the lining is greater than 8
mm, Femonston (estace and dydrogesterone)
8mg/d can be started.
1. The day femonston is started is considered
ovulation/opu day, and the time of thaw/transfer is
determined accordingly.
2. If oral E2 is not sufficient, E2 can also be given
through vaginal routes. Femonston (estrace)
1mg/d by vaginal route has good effects for the
patients with thin endometrium.
AboubakrElnashar
For the patients with menstrual cycle more than 40
days: dose of letrozole is 5mg qd for 5 days.
for the patients with cycle 35-40 days, the dose of
letrozole commonly use 5mg for 3 days.
for the patients with cycle less than 28 days, the
dose of letrozole is recommended 2.5mg for 3-5
days.
For purpose of synchronization day of HCG
administration correspond to the HCG administration
day of the source cycle in which the Embryos were
retrived
AboubakrElnashar
For the patients can not build the lining with the
above methods
1. office hysterscopy before FET.
2. if the endometrium is present pale mucous and
insufficiency bloold flow, docotors will scissor
endometrium gently.
3. Intrauterine scar tissue canbe removed with hyste
roscopy, intrauterine device will be placed for a
few months to prevent further adhesion formation
when necessary.
(Yanping Kuang)
AboubakrElnashar

Mais conteúdo relacionado

Mais procurados

Management of Poor Responders
Management of Poor RespondersManagement of Poor Responders
Management of Poor RespondersSandro Esteves
 
Ovarian Stimulation Protocols
Ovarian Stimulation ProtocolsOvarian Stimulation Protocols
Ovarian Stimulation ProtocolsHesham Gaber
 
Repeated Implantation failure
Repeated Implantation failureRepeated Implantation failure
Repeated Implantation failureAhmad Saber
 
Management of thin endometrium isar 2019
Management of thin endometrium isar 2019Management of thin endometrium isar 2019
Management of thin endometrium isar 2019Poonam Loomba
 
Luteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVF
Luteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVFLuteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVF
Luteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVFDr.Laxmi Agrawal Shrikhande
 
Individualizing Ovarian Stimulation Protocols for IVF
Individualizing Ovarian Stimulation Protocols for IVFIndividualizing Ovarian Stimulation Protocols for IVF
Individualizing Ovarian Stimulation Protocols for IVFSherInstitute
 
Day3 versus Day5 Embryo Transfer
Day3 versus Day5 Embryo TransferDay3 versus Day5 Embryo Transfer
Day3 versus Day5 Embryo TransferSujoy Dasgupta
 
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain Lifecare Centre
 
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLESENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLESfatihkaraosmanoglu.net
 
Unexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dr Dhorepatil BharatiUnexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dr Dhorepatil BharatiBharati Dhorepatil
 
Luteal phase support in ivf
Luteal phase support in ivfLuteal phase support in ivf
Luteal phase support in ivfmagdy abdel
 
Managing poor responder
Managing poor responderManaging poor responder
Managing poor responderG A RAMA Raju
 

Mais procurados (20)

Management of Poor Responders
Management of Poor RespondersManagement of Poor Responders
Management of Poor Responders
 
Ovarian Stimulation Protocols
Ovarian Stimulation ProtocolsOvarian Stimulation Protocols
Ovarian Stimulation Protocols
 
Repeated Implantation failure
Repeated Implantation failureRepeated Implantation failure
Repeated Implantation failure
 
Management of thin endometrium isar 2019
Management of thin endometrium isar 2019Management of thin endometrium isar 2019
Management of thin endometrium isar 2019
 
Fet endometrial preparation
Fet endometrial preparationFet endometrial preparation
Fet endometrial preparation
 
Luteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVF
Luteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVFLuteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVF
Luteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVF
 
EMPTY FOLLICLE SYNDROME
EMPTY FOLLICLE SYNDROMEEMPTY FOLLICLE SYNDROME
EMPTY FOLLICLE SYNDROME
 
Individualizing Ovarian Stimulation Protocols for IVF
Individualizing Ovarian Stimulation Protocols for IVFIndividualizing Ovarian Stimulation Protocols for IVF
Individualizing Ovarian Stimulation Protocols for IVF
 
Treatment of decreased ovarian reserve
Treatment of decreased ovarian reserveTreatment of decreased ovarian reserve
Treatment of decreased ovarian reserve
 
Day3 versus Day5 Embryo Transfer
Day3 versus Day5 Embryo TransferDay3 versus Day5 Embryo Transfer
Day3 versus Day5 Embryo Transfer
 
OVARIAN RESERVE
OVARIAN RESERVEOVARIAN RESERVE
OVARIAN RESERVE
 
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain
 
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLESENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
 
Optimizing IUI Outcome
Optimizing IUI OutcomeOptimizing IUI Outcome
Optimizing IUI Outcome
 
Thin Endometrium
Thin EndometriumThin Endometrium
Thin Endometrium
 
Unexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dr Dhorepatil BharatiUnexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dr Dhorepatil Bharati
 
Luteal phase support in ivf
Luteal phase support in ivfLuteal phase support in ivf
Luteal phase support in ivf
 
Markers of ovarian reserve presentation
Markers of ovarian reserve presentationMarkers of ovarian reserve presentation
Markers of ovarian reserve presentation
 
Managing poor responder
Managing poor responderManaging poor responder
Managing poor responder
 
Ivf in pcos
Ivf in pcosIvf in pcos
Ivf in pcos
 

Destaque

Factors affecting success of embryo transfer
Factors affecting success of embryo transferFactors affecting success of embryo transfer
Factors affecting success of embryo transferAboubakr Elnashar
 
Optimizing Embryo Transfer in IVF Cycles
Optimizing Embryo Transfer in IVF CyclesOptimizing Embryo Transfer in IVF Cycles
Optimizing Embryo Transfer in IVF CyclesUlun Uluğ
 
The limits to the number of EMBRYO TO TRANSFER. Prof Aboubakr Elnashar
The limits to the number of EMBRYO TO TRANSFER. Prof Aboubakr ElnasharThe limits to the number of EMBRYO TO TRANSFER. Prof Aboubakr Elnashar
The limits to the number of EMBRYO TO TRANSFER. Prof Aboubakr ElnasharAboubakr Elnashar
 
In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...
In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...
In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...Ahmed Mowafy
 
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHARPERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHARAboubakr Elnashar
 
Embryo transfer: Aboubakr Elnashar
Embryo transfer: Aboubakr ElnasharEmbryo transfer: Aboubakr Elnashar
Embryo transfer: Aboubakr ElnasharAboubakr Elnashar
 
In vitro fertilization and embryo transfer in humans
In vitro fertilization and embryo transfer in humansIn vitro fertilization and embryo transfer in humans
In vitro fertilization and embryo transfer in humansHasnahana Chetia
 
In vitro fertilization embryo transfer
In vitro fertilization embryo transferIn vitro fertilization embryo transfer
In vitro fertilization embryo transferNiyamat Panjesha
 

Destaque (13)

Embryo transfer
Embryo transferEmbryo transfer
Embryo transfer
 
Embryo Transfer report
Embryo Transfer reportEmbryo Transfer report
Embryo Transfer report
 
Factors affecting success of embryo transfer
Factors affecting success of embryo transferFactors affecting success of embryo transfer
Factors affecting success of embryo transfer
 
Optimizing Embryo Transfer in IVF Cycles
Optimizing Embryo Transfer in IVF CyclesOptimizing Embryo Transfer in IVF Cycles
Optimizing Embryo Transfer in IVF Cycles
 
The limits to the number of EMBRYO TO TRANSFER. Prof Aboubakr Elnashar
The limits to the number of EMBRYO TO TRANSFER. Prof Aboubakr ElnasharThe limits to the number of EMBRYO TO TRANSFER. Prof Aboubakr Elnashar
The limits to the number of EMBRYO TO TRANSFER. Prof Aboubakr Elnashar
 
Embryo transfer
Embryo transferEmbryo transfer
Embryo transfer
 
In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...
In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...
In vitro fertilization and embryo transfer "IVF"; Overview on the Story FRO...
 
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHARPERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
 
Embryo transfer: Aboubakr Elnashar
Embryo transfer: Aboubakr ElnasharEmbryo transfer: Aboubakr Elnashar
Embryo transfer: Aboubakr Elnashar
 
In vitro fertilization and embryo transfer in humans
In vitro fertilization and embryo transfer in humansIn vitro fertilization and embryo transfer in humans
In vitro fertilization and embryo transfer in humans
 
Diseases of vulva
Diseases of vulvaDiseases of vulva
Diseases of vulva
 
Era protocol 2017
Era protocol 2017Era protocol 2017
Era protocol 2017
 
In vitro fertilization embryo transfer
In vitro fertilization embryo transferIn vitro fertilization embryo transfer
In vitro fertilization embryo transfer
 

Semelhante a Guide to Endometrial Preparation Methods in Frozen Embryo Transfer Cycles

Therapeutic uses of Progestagen in infertility and IVF
Therapeutic uses of  Progestagen  in infertility and IVF Therapeutic uses of  Progestagen  in infertility and IVF
Therapeutic uses of Progestagen in infertility and IVF Aboubakr Elnashar
 
Progesterone in clinical practice
Progesterone in clinical practiceProgesterone in clinical practice
Progesterone in clinical practiceAboubakr Elnashar
 
New developments in reproductive medicine (1)
New developments in reproductive medicine (1)New developments in reproductive medicine (1)
New developments in reproductive medicine (1)鋒博 蔡
 
複製 New developments in reproductive medicine
複製  New developments in reproductive medicine複製  New developments in reproductive medicine
複製 New developments in reproductive medicinet7260678
 
New developments in reproductive medicine (1)
New developments in reproductive medicine (1)New developments in reproductive medicine (1)
New developments in reproductive medicine (1)t7260678
 
New developments in reproductive medicine
New developments in reproductive medicineNew developments in reproductive medicine
New developments in reproductive medicinet7260678
 
New developments in reproductive medicine (1)
New developments in reproductive medicine (1)New developments in reproductive medicine (1)
New developments in reproductive medicine (1)鋒博 蔡
 
New developments in reproductive medicine
New developments in reproductive medicineNew developments in reproductive medicine
New developments in reproductive medicine鋒博 蔡
 
New developments in reproductive medicine
New developments in reproductive medicineNew developments in reproductive medicine
New developments in reproductive medicine鋒博 蔡
 
Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...
Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...
Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...lukeman Joseph Ade shittu
 
New Developments In Reproductive Medicine
New Developments In Reproductive MedicineNew Developments In Reproductive Medicine
New Developments In Reproductive Medicineguest7f0a3a
 
Ovarian waves and random ovarian stimulation
Ovarian waves and random ovarian stimulationOvarian waves and random ovarian stimulation
Ovarian waves and random ovarian stimulationmohamedbehery2
 
Ovarian Hyperstimulation in Intrauterine Insemination
Ovarian Hyperstimulation in Intrauterine InseminationOvarian Hyperstimulation in Intrauterine Insemination
Ovarian Hyperstimulation in Intrauterine InseminationElmar Breitbach
 
Cordes sao paulo_29_11
Cordes sao paulo_29_11Cordes sao paulo_29_11
Cordes sao paulo_29_11鋒博 蔡
 
Cordes sao paulo_29_11 (1)
Cordes sao paulo_29_11 (1)Cordes sao paulo_29_11 (1)
Cordes sao paulo_29_11 (1)鋒博 蔡
 
Cordes sao paulo_29_11 (1)
Cordes sao paulo_29_11 (1)Cordes sao paulo_29_11 (1)
Cordes sao paulo_29_11 (1)鋒博 蔡
 
Cordes sao paulo_29_11
Cordes sao paulo_29_11Cordes sao paulo_29_11
Cordes sao paulo_29_11鋒博 蔡
 
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...Sandro Esteves
 
Flexible gn rh antagonist protocol.full
Flexible gn rh antagonist protocol.fullFlexible gn rh antagonist protocol.full
Flexible gn rh antagonist protocol.fullNana Novruzova
 

Semelhante a Guide to Endometrial Preparation Methods in Frozen Embryo Transfer Cycles (20)

Therapeutic uses of Progestagen in infertility and IVF
Therapeutic uses of  Progestagen  in infertility and IVF Therapeutic uses of  Progestagen  in infertility and IVF
Therapeutic uses of Progestagen in infertility and IVF
 
Progesterone in clinical practice
Progesterone in clinical practiceProgesterone in clinical practice
Progesterone in clinical practice
 
New developments in reproductive medicine (1)
New developments in reproductive medicine (1)New developments in reproductive medicine (1)
New developments in reproductive medicine (1)
 
複製 New developments in reproductive medicine
複製  New developments in reproductive medicine複製  New developments in reproductive medicine
複製 New developments in reproductive medicine
 
New developments in reproductive medicine (1)
New developments in reproductive medicine (1)New developments in reproductive medicine (1)
New developments in reproductive medicine (1)
 
New developments in reproductive medicine
New developments in reproductive medicineNew developments in reproductive medicine
New developments in reproductive medicine
 
New developments in reproductive medicine (1)
New developments in reproductive medicine (1)New developments in reproductive medicine (1)
New developments in reproductive medicine (1)
 
New developments in reproductive medicine
New developments in reproductive medicineNew developments in reproductive medicine
New developments in reproductive medicine
 
New developments in reproductive medicine
New developments in reproductive medicineNew developments in reproductive medicine
New developments in reproductive medicine
 
Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...
Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...
Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...
 
New Developments In Reproductive Medicine
New Developments In Reproductive MedicineNew Developments In Reproductive Medicine
New Developments In Reproductive Medicine
 
Ovarian drilling
Ovarian drillingOvarian drilling
Ovarian drilling
 
Ovarian waves and random ovarian stimulation
Ovarian waves and random ovarian stimulationOvarian waves and random ovarian stimulation
Ovarian waves and random ovarian stimulation
 
Ovarian Hyperstimulation in Intrauterine Insemination
Ovarian Hyperstimulation in Intrauterine InseminationOvarian Hyperstimulation in Intrauterine Insemination
Ovarian Hyperstimulation in Intrauterine Insemination
 
Cordes sao paulo_29_11
Cordes sao paulo_29_11Cordes sao paulo_29_11
Cordes sao paulo_29_11
 
Cordes sao paulo_29_11 (1)
Cordes sao paulo_29_11 (1)Cordes sao paulo_29_11 (1)
Cordes sao paulo_29_11 (1)
 
Cordes sao paulo_29_11 (1)
Cordes sao paulo_29_11 (1)Cordes sao paulo_29_11 (1)
Cordes sao paulo_29_11 (1)
 
Cordes sao paulo_29_11
Cordes sao paulo_29_11Cordes sao paulo_29_11
Cordes sao paulo_29_11
 
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
 
Flexible gn rh antagonist protocol.full
Flexible gn rh antagonist protocol.fullFlexible gn rh antagonist protocol.full
Flexible gn rh antagonist protocol.full
 

Mais de Aboubakr Elnashar

WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTWHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTAboubakr Elnashar
 
Adenomyosis associated infertility
Adenomyosis associated  infertilityAdenomyosis associated  infertility
Adenomyosis associated infertilityAboubakr Elnashar
 
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Aboubakr Elnashar
 
Aesthetic gynecology controversy
Aesthetic gynecology controversyAesthetic gynecology controversy
Aesthetic gynecology controversyAboubakr Elnashar
 
Hormonal assay in clinical gyn
Hormonal assay in clinical gynHormonal assay in clinical gyn
Hormonal assay in clinical gynAboubakr Elnashar
 
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineUnnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineAboubakr Elnashar
 
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationIndividualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationAboubakr Elnashar
 
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA Aboubakr Elnashar
 
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021  cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021 Aboubakr Elnashar
 
Management of pregnancy of unknown location
Management of pregnancy of unknown locationManagement of pregnancy of unknown location
Management of pregnancy of unknown locationAboubakr Elnashar
 
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021Aboubakr Elnashar
 

Mais de Aboubakr Elnashar (20)

WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTWHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
 
hepatitis B.pdf
hepatitis B.pdfhepatitis B.pdf
hepatitis B.pdf
 
hepatitis c2022.pdf
hepatitis c2022.pdfhepatitis c2022.pdf
hepatitis c2022.pdf
 
Adenomyosis associated infertility
Adenomyosis associated  infertilityAdenomyosis associated  infertility
Adenomyosis associated infertility
 
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022
 
Adenxal mass guidelines2020
Adenxal mass guidelines2020Adenxal mass guidelines2020
Adenxal mass guidelines2020
 
Aesthetic gynecology controversy
Aesthetic gynecology controversyAesthetic gynecology controversy
Aesthetic gynecology controversy
 
Hormonal assay in clinical gyn
Hormonal assay in clinical gynHormonal assay in clinical gyn
Hormonal assay in clinical gyn
 
FIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVFFIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVF
 
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineUnnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicine
 
Infertility prevention
Infertility prevention Infertility prevention
Infertility prevention
 
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationIndividualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulation
 
Female infertility
Female infertility Female infertility
Female infertility
 
Maternal near miss
Maternal near missMaternal near miss
Maternal near miss
 
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
 
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021  cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021
 
CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT  CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT
 
Management of pregnancy of unknown location
Management of pregnancy of unknown locationManagement of pregnancy of unknown location
Management of pregnancy of unknown location
 
Aerobic Vaginitis
Aerobic Vaginitis Aerobic Vaginitis
Aerobic Vaginitis
 
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021
 

Último

Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Screening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxScreening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxtadehabte
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfSasikiranMarri
 
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfCCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfMyThaoAiDoan
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medicationMohamadAlhes
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 

Último (20)

Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Screening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxScreening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptx
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
 
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfCCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medication
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 

Guide to Endometrial Preparation Methods in Frozen Embryo Transfer Cycles

  • 1. ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES Aboubakr Elnashar Benha university, Egypt AboubakrElnashar
  • 2. CONTENTS INTRODUCTION I. NATURAL CYCLE II. ARTIFICIAL (HORMONE REPLACEMENT) CYCLE III. OVULATION INDUCTION CONCLUSION AboubakrElnashar
  • 3. INTRODUCTION 1st successful pregnancy following FET: 1983 Trounson and Mohr (Trounson, 1983).  Cryopreservation of embryos has become an integral part of ART programs.  Increased dramatically  1.Ttrend towards transferring fewer embryos after a fresh IVF cycle  2. Improved laboratory techniques  (Skovmand 1997; Diniz, 2002; Fineschi et al., 2005; Gordts et al., 2005; Thompson, 2005; Le Lannou et al., 2006; JOINT SOGC-CFAS, 2008; Min et al., 2010). AboubakrElnashar
  • 4. Success= keypoints in performing FET 1. Selecting proper embryos used for FET •Cleavaged embryos with grade I or II, and present ≥6 blastomeres at D3 are the right kind. •Embryos with 4 blastomere: continue in vitro culture to reach the stage of 8 blastomere then perform vitrification cryopreservation. •Non-high quality embryos: continue to culture them into blasocyst and select the valid blastocyst for cryopreservation. This step is important for settling the appropriate time for ET AboubakrElnashar
  • 5. 2. Accurate synchronization of endometrium and embyos is the key of performing FET. Important for implantation  Age of the embryos after thawing corresponds to age of the endometrium on the day of ET 3. Sufficient luteal support AboubakrElnashar
  • 6. Methods: Regular ovulatory Irregular or unovulatory I. Natural II. Artificial=Hormone replacement III. Ovulation induction True Modified E and P Gna, E and P GnT Letrozole Nolvadex Functioning ovaries: Any method Quiescent Ovaries (e.g. donor oocyte recepient with ovarian failure) Only HRT with E and P Many infertility units use a mixture of protocols for FET. AboubakrElnashar
  • 7. Best method: Little agreement in ovulatory women (Ghobara and Vandekerckhove, 2008;Weissman et al., 2009). AboubakrElnashar
  • 8. I. NATURAL CYCLE NC-FET  Indication It is only feasible for women with regular cycles and proven ovulation. In normally ovulating women: protocol of choice  The simplest method  Endocrine preparation of the endometrium is achieved by endogenous sex steroid production from a developing follicle. AboubakrElnashar
  • 9. A. True Natural cycle  Timing of ET is determined by detecting the spontaneous LH surge Method: 1. D10-12 (3-5 d prior to estimated ovulation day)  Serial US: E thickness, follicular development and to time the commencement of testing for LH  LH (urine or blood) for detection of the LH surge ,  P levels When a rise in serum LH levels is observed, it is assumed that ovulation will occur 36–40 h later (Andersen et al., 1995). LH surges in urine lag up to 21 h behind the appearance of the surge in blood (Hoff et al., 1983; Frydman et al., 1984; Miller and Soules 1996). The day when LH exceeds 180% of baseline (calculated as the mean of the 3 previous morning samples) corresponds to a day prior to OPU/ovulation. 2. US for evidence of ovulation. AboubakrElnashar
  • 10. 3. FET 3–5 days after ovulation depending on the stage of the embryo when frozen The day of ovulation corresponds to the day of egg retrieval. If embryos were frozen at 72h, ovulation day+3 is the right time to transfer. (Nawroth and Ludwig, 2005; Paulson,2011). 4. LPS: progesterone AboubakrElnashar
  • 11. Advantage no medications are used: preferable to many women. AboubakrElnashar
  • 12. Disadvantages: 1. Even in women having regular menstrual cycles, ovulation may not always occur 2. Problem associated with the detection of spontaneous LH surges A. variation in timing of its occurrence between cycles and between patients (Park et al., 2007). B. In order to assess the LH levels correctly, determination should be performed at least daily, and preferably twice a day. C. LH urine kits have a large variation in thresholds, which involve the risk of up to 30% of false- negative testing, and are often reported by patients as being difficult to interpret (Miller and Soules, 1996; Guermandi et al., 2001; O’Connor et al., 2006). AboubakrElnashar
  • 13. B. Modified natural cycle To overcome the disadvantages of LH monitoring: Administering hCG to initiate luteinization Method: 1. Regular US: 2. HCG 5000 IU when dominant follicle (16 or 17or 18 mm): ovulation 36–38 h later (Andersen et al., 1995). Combined with E2 levels of (450-550 pmol/L), 600-700 or 800-900 respectively HCG administration correspond to the HCG administration day of the source cycle AboubakrElnashar
  • 14. Zheng et al, 2014 AboubakrElnashar
  • 15. Advantages: less US evaluation due to the hCG administration compared with true NC-FET: less burden on patients and doctors (Weissman et al., 2011). AboubakrElnashar
  • 16. Risks 1. unexpected ovulation : accurate planning of embryo thawing and transfer is not possible: cycle cancellation (7–12%) (Fatemi et al., 2010; Hill et al., 2010). 2. Difficulty in ensuring timely thawing and ET. AboubakrElnashar
  • 17. LPS in NC-FET. Not required (Kyrou et al, 2010) similar result in patients receiving true NC-FET (Lee et al., 2013). {CL formation is not hampered by inadequate LH secretion} higher LBR in patients undergoing true NC-FET with LPS. (Bjuresten et al. 2011) Too little evidence supporting a positive effect of LPS in patients undergoing NC-FET (Groenewoud et al, 2013, MA) AboubakrElnashar
  • 18. True NC-FET Vs modified NC-FET: no difference in outcome AboubakrElnashar
  • 19. II. ARTIFICIAL (HORMONE REPLACEMENT) CYCLE In patients with irregular cycles HRT is best used. Aims To mimic the endocrine exposure of the endometrium in the normal cycle. AboubakrElnashar
  • 20. Key points: 1.An endometrial thickness 6 and showing triple line is favorable for ET 2.Endometrial development is unaffected by the length of the follicular phase. No adverse effects of reduction the duration of exposure to E to 6 days or an increase up to 35 days. However receptivity is best preserved when the follicular phase is kept between 12 and 19 days 3.The endometrium is affected by either incremental or fixed E levels , even in supraphysiologic range AboubakrElnashar
  • 21. A. Estrogens and progesterones without GnRHa. used in women with remaining ovarian function (Jaroudi 1991; Lelaidier 1992). Method: 1. Oestrogen Effect: proliferation of the endometrium, while suppressing the development of the dominant follicle  Form and dose  Oral E2 (progynova or Trisequence (Blue tab) or Cycloprogenova (White tab)) 4-6 mg/d or 2 mg/d with an increasing doses  Transdermal patches (estrofem/estrace)  subcutaneous implants  vaginal rings or tablets. AboubakrElnashar
  • 22.  When:  D1 of cycle: prevents follicular recruitment by suppressing FSH: spontaneous ovulation is avoided.  D3 before D4. AboubakrElnashar
  • 23. 2. Progesterone Aim: initiate secretory changes Form oral tablets IM 40-60 mg in oil vaginal suppositories, gel or rings (Devroey 1998). When Once the lining endometrium: 7–9 mm on US Not duration of E2 supplementation but the endometrium thickness should be the leading factor in determining the start of progesterone (Nawroth and Ludwig, 2005; El-Toukhy et al., 2008). AboubakrElnashar
  • 24. Route: No difference in PR between vaginal and IM progesterone. (Glujovsky et al., 2010, SR) based on patient and doctor preference. AboubakrElnashar
  • 25. Timing of embryo thawing and ET: Planned according to the moment of progesterone supplementation. The day P is started is considered ovulation/opu day, and the time of thaw/transfer is determined accordingly. AboubakrElnashar
  • 26. 1. E2 From D2 or 3 of cycle: 3 or 4 tab (acc to wt of pt) (for 7 or 8 days) 2. US: When endometrial thickness 9 mm 3. Prontogest 400 mg twice daily or duphaston 10 mg tds 4. ET If you are freezing Blastocyst: transfer on 6th or 7th day of progesterone D3 or Morula: transfer on day 4 of progesterone (some say D 5 for all, no difference) 4. LPS Estrogen and progesterone AboubakrElnashar
  • 27. Cases of amenorrhea (after induction by lutone or lutofolon or cycloprognova or pills) 1. E2 1 Tab x 3 day from D3 of the cycle 2 Tab x 3 day 3 Tab x (2 – 5 day ) 2. TVS monitoring till endometrial lining is 9 – 10 mm. 3. Uterogestan1 tab of utrogestan/d E2: 2 Tab/d till pregnancy test 4. ET 5. LPS: if preg test positive: utrogestan 2X3 AboubakrElnashar
  • 28. 1. Oral E2 2 mg/d from cycle day 1-4 4 mg/d from day 5-8 6 mg/d from day 9-12. 2. TVS: assess endometrial-thickness and ovulation from D13 and E2 dosage was adjusted based on the endometrial-thickness. 3. P: 40 mg IM when the endometrium reached a thickness of 8 mm or maximum. 60 mg, 80 mg, and 80 mg progesterone were used respectively in the following 3 days. 4. ET after 4 days of progesterone administration. AboubakrElnashar
  • 29. 1. Oral E2: 2 mg three times daily. 2. TVS: After 11, 12 or 13 days A. If no leading follicle is present and the endometrial thickness is ≥ 8 mm: micronized progesterone (utrogestan) is added and thawing and transferring is commenced 4 or 5 days later according to the stage of cryopreservation B. If the endometrial thickness is less than 8 mm: progynova dose is raised to 2 mg 4 times daily for 7 days. After a week the endometrium is checked once again.  When the endometrium thickness is >8 mm and no dominant follicle (≥ 14 mm) is present: utrogestan can be added and thawing and transferring is performed according to local protocols.  If a follicle is visible during ultrasound: LH and P levels are determined. • If these are raised, (serum LH ≥ 13 E/l or progesterone ≥ 15 nmol/l) luteinization of the follicle is considered to have taken place and because of the associated diminished pregnancy rates, thawing and transferring will not be performed. • If serum levels are below the above mentioned levels thawing and transferring can be performed according to local protocol AboubakrElnashar
  • 30. Zheng et al, 2014 AboubakrElnashar
  • 31. Advantages 1. Greater control and flexibility in the timing of transfer. cycles are easier to plan: popular among many patients and their doctors. 2. The length of the follicular phase can be varied without detriment to IR or PR (Leeton 1991; Navot 1989) 3. Cycle cancellation rate is low. AboubakrElnashar
  • 32. 4. Higher IR and PR than patients with natural cycles IR and PR was higher in patients without ovulation than ovulatory patients ovulation in HRT cycle has a detrimental effect on pregnancy. HRT should be used in FET cycles, and ovulation of patients should be evaluated during the treatment. Zheng et al, 2014 AboubakrElnashar
  • 33. Risks: 1. The administration of E and P does not guarantee complete pituitary suppression: a dominant follicle may occur. luteinization may occur in 5% (El Toukhy et al., 2004). 2. Should the follicle undergo spontaneous luteinization: endometrium may be exposed to progesterone earlier: incorrect timing of thawing and transferring. From a cost-efficiency perspective, this aspect is of great importance and should be taken into account GnRHa co-treatment may be used to down- regulate the pituitary and prevent follicular growth (AC-FET with GnRH-FET). AboubakrElnashar
  • 34. 3. Both of these AC-FET approaches require medication and are therefore less ‘physiological’ AboubakrElnashar
  • 36. LPS: If a pregnancy occurs, E and P must be continued until placental autonomy is established to replace the absent corpus luteum. No difference in PR between different methods of LPS in patients undergoing ‘fresh’ IVF or ICSI (Chocrane SR, van der Linden et al., 2011). The use of synthetic progesterone in patients undergoing IVF or ICSI did lead to higher PR compared with natural progesterone. AboubakrElnashar
  • 37. B. Estrogens and progesterones with GnRHa. Indication: In women with remaining ovarian function Aim: GnRHa is used to suppress temporarily ovarian function and render the patient functionally agonadal prior to inducing an artificial cycle with E and P. Method: 1. GnRHa (Decapeptyl CR, 3.75 mg) in regularly menstruating it is given on D21 of the cycle in oligomenorrhic from D1 of the cycle. 2. After 14 days: E2 is determined E2 is started as before AboubakrElnashar
  • 39. Disadvantages: 1. More expensive 2. GnRHa can have side effects 3. Delay the resumption of spontaneous ovulation if FET fails. AboubakrElnashar
  • 40. AC-FET Vs AC-FET with GnRH Cost is less Cancellation due to luteinization occurs in 5% is more No significant difference in PR AboubakrElnashar
  • 41. NC-FET Vs AC-FET. No difference in PR. AboubakrElnashar
  • 42. NC-FET Vs AC-FET with GnRHa: No significant difference in PR or LBR. (Ghobara and Vandekerckhove,2008) Significantly higher cancellation rates in NC-FET (17.4%) Vs AC-FET with GnRH (4.5%) {preventive effect of down-regulation with regard to luteinization and ovulation}. (Hill et al., 2010). AboubakrElnashar
  • 43. III. OVULATION INDUCTION Ovary is functional but anovulatory and irregular cycles, ovulation may be induced by CC, Nolvadex, letrozole or hMG or or a combination (Van der Auwera;1994). For synchronization the day of HCG administration should correspond to the day HCG administration of the source cycle in which the embryos were retrieved AboubakrElnashar
  • 44. A. Letrozole, GNT In patients with irregular cycles Letrozole is 1st choice for endometrium preparation for FET 1. Letrozole: 2.5-5mg on cycle D3 to 7, in order to promote monofollicular development 2. TVS: if follicles growth is not ideal: mild stimulation (HMG 150 IU) 3. HCG: 10000: when the follicles reach the criteria of mature 4. ET Embryos were frozen at 72h: ETAfter 4 or 5 days Blastocyst transfer is performed after 7 days. AboubakrElnashar
  • 45. 1. Letrozole 2.5mg,once daily from D3 to D7 of cycle 2. TVS D10 of cycle: IM Gnt 37.5~75 IU/d until there is LH surge or ovulation 3. HCG  On the day appearing LH surge: IM HCG10000 IU.  If there is sill no LH surge when the follicle is 20- 24mm: ovulation is induced by HCG. 4. ET 3 days after ovulation is observed. 4. LPS: HCG 2000-2500 IU/3d. AboubakrElnashar
  • 46. B. Letrozole or nolvadex, E2 1. Letrozole: 1x1 x 5 or Nolvadex 1x3x5 from D3 of the period 2. E2 1x2x3 from D 8 - 9th day of period (follicle 12-14mm) 1x3x3 3. TVS: from D10-11 till endometrial lining 9-11 mm 4. HCG 4. ET after 3.5 Days for the 2 days frozen embryo or after 4.5 Days for the 3 days frozen embryo 5. LPS: E2: 1x2x12 w of pregnancy. Cyclogest 200mg 2 days before E.T Then Cyclogest 400mg after E.T. till 12w AboubakrElnashar
  • 47. C. CC, E2 1.CC Start D 3 to 5 of menstruation or withdrawal for 5 days 2. E2 2mg/d until D of HCG administration to overcome detrimental effect of CC on endometrium. 3. HCG Repeated testing of P with US P within follicular levels adequate follicular size (20-24 mm) and E thickness ≥8mm: HCG 10000 AboubakrElnashar
  • 48. D. Chronic low dose GnT Anovulatory patients resistant to CC: 1.FSH 37.5 -75 U /d for up to 14 days 2. TVS if no dominant F is recruited , the dose is increased at increments 37.5 U every week to a maximum 225 U/d When single dominant F of 10-12 mm the dose is maintained 3. Monitor by US and E2 and P AboubakrElnashar
  • 49. CONCLUSION It is not possible, to recommend one endometrial preparation method in FET over another Future RCTs should not only address PR but also consider convenience and cost efficiency. No significant advantage of one specific approach to prepare the endometrium for FET in terms of PR or LBR. (Ghobara and Vandekerckhove, 2008; Groenewoud et al, 2013, MA) AboubakrElnashar
  • 50. Choice for either NC or AC should be made based upon other factors: 1. number of canceled cycles 2. number of hospital visits to plan FET 3. possible serious adverse events and side-effects 4. hospital and IVF laboratory logistics 5. patient or doctor preference. No publications that address these factors AboubakrElnashar
  • 52. For the patients with thin endometrium or multiple ET failures, HRT 1. Oral E2 (ethinyloestradiol) is given 75ug/day for 14-28 days. Once the lining is greater than 8 mm, Femonston (estace and dydrogesterone) 8mg/d can be started. 1. The day femonston is started is considered ovulation/opu day, and the time of thaw/transfer is determined accordingly. 2. If oral E2 is not sufficient, E2 can also be given through vaginal routes. Femonston (estrace) 1mg/d by vaginal route has good effects for the patients with thin endometrium. AboubakrElnashar
  • 53. For the patients with menstrual cycle more than 40 days: dose of letrozole is 5mg qd for 5 days. for the patients with cycle 35-40 days, the dose of letrozole commonly use 5mg for 3 days. for the patients with cycle less than 28 days, the dose of letrozole is recommended 2.5mg for 3-5 days. For purpose of synchronization day of HCG administration correspond to the HCG administration day of the source cycle in which the Embryos were retrived AboubakrElnashar
  • 54. For the patients can not build the lining with the above methods 1. office hysterscopy before FET. 2. if the endometrium is present pale mucous and insufficiency bloold flow, docotors will scissor endometrium gently. 3. Intrauterine scar tissue canbe removed with hyste roscopy, intrauterine device will be placed for a few months to prevent further adhesion formation when necessary. (Yanping Kuang) AboubakrElnashar